AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24226297
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of the intervention (three or more components).
Trial: 23241063
Drug: Ultrasound-guided cervical
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided cervical periradicular steroid injection (US-CPSI)
Trial: 21397530
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (endovascular and/or surgical)
Trial: 16192421
Drug: Standard-dose hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose hemodialysis
Trial: 12783106
Drug: Enoxaparin monotherapy
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin monotherapy (1 mg/kg twice daily for 14 days, then randomized to 1.0 mg/kg vs. 1.5 mg/kg once daily)
Trial: 16444853
Drug: Enoxaparin monotherapy
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin monotherapy
Trial: 12783106
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin as a bridge to warfarin (target INR 2.0-3.0)
Trial: 12783106
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin as a bridge to warfarin
Trial: 10993961
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with mitomycin C (15 mg/M(2) on the first and sixth week of radiotherapy)
Trial: 8791049
Drug: estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estramustine phosphate 600 mg/m2 orally daily for 2 years
Trial: 8791049
Drug: cyclophosphamide 1
RxNorm normalized name: cyclophosphamide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years
Trial: 8791049
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment (observation only)
Trial: 1538722
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg per day given orally)
Trial: 1538722
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (1 mg per kilogram of body weight per week given intravenously)
Trial: 6548925
Drug: Antacid A
RxNorm normalized name: Antacid Anti-Gas
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid A (aluminium‐magnesium hydroxide codried gel, aluminium hydroxide, calcium carbonate)
Trial: 6548925
Drug: Antacid A
RxNorm normalized name: Antacid Anti-Gas
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid A
Trial: 30264287
Drug: Control (pre‐preparation)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (pre‐preparation)
Trial: 19215577
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg qd
Trial: 16498265
Drug: L-NAME (NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (NO synthase inhibitor)
Trial: 16498265
Drug: Aspirin (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (prostaglandin inhibitor)
Trial: 16498265
Drug: Cetirizine (H1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (H1 receptor antagonist)
Trial: 14623703
Drug: HuMax-CD4 20
RxNorm normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-CD4 20 mg
Trial: 14623703
Drug: HuMax-CD4 80
RxNorm normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-CD4 80 mg
Trial: 14623703
Drug: HuMax-CD4 160
RxNorm normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-CD4 160 mg
Trial: 14623703
Drug: HuMax-CD4 280
RxNorm normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-CD4 280 mg
Trial: 8018638
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of mifepristone
Trial: 3901936
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg prostaglandin E2 (PGE2) gel
Trial: 23981321
Drug: Word-learning training,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Word-learning training, 2-weekly sessions across 10 weeks
Trial: 20812958
Drug: L-carnitine supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplement (1000 mg/d for 12 weeks)
Trial: 20812958
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-carnitine supplement)
Trial: 10948088
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg/kg per hour)
Trial: 10948088
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (1 to 3 mg/h)
Trial: 8980592
Drug: Maloprim (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maloprim (6.25 mg pyrimethamine + 50 mg dapsone for children under 10 years, and 12.5 mg pyrimethamine + 100 mg dapsone for children 10 or more years old as a single dose)
Trial: 3914621
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of retinoids
Trial: 3914621
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of retinoids
Trial: 3914621
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid administration
Trial: 31580693
Drug: I-gel mask
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-gel mask
Trial: 31580693
Drug: Both I-gel
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both I-gel and Baska masks
Trial: 17219216
Drug: MDMA (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (75 and 50 mg)
Trial: 11993408
Drug: Potassium losartan
RxNorm normalized name: Losartan Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium losartan 50 mg per day
Trial: 8188888
Drug: Topical calcitriol
RxNorm normalized name: calcitriol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcitriol (3 micrograms/gm) applied twice daily for 6 weeks
Trial: 3796920
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of prostaglandin E1 analogue (ONO-802)
Trial: 30866893
Drug: HBV vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccination (94.2% reported vaccination; 4.7% with 2 doses, 58.1% with 3 doses, 37.2% took a booster)
Trial: 30127247
Drug: EGCG (752
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (752 mg)
Trial: 30127247
Drug: Placebo (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (800 mg corn starch)
Trial: 26961597
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of tranexamic acid (TXA) mixed in 100 mL normal saline
Trial: 26961597
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of normal saline
Trial: 25200415
Drug: QGE031 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 (2 mg/kg)
Trial: 25200415
Drug: QGE031 (0.1-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 (0.1-10 mg/kg) or placebo (IV)
Trial: 25200415
Drug: QGE031 (0.2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 (0.2-4 mg/kg) or placebo (SC)
Trial: 25200415
Drug: QGE031 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 (10 mg/kg)
Trial: 21166111
Drug: Once-daily Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily Tacrolimus Extended Release (Tac ER)
Trial: 21166111
Drug: Twice-daily Cyclosporine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily Cyclosporine (CsA)
Trial: 25247335
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/day for 12 weeks)
Trial: 9869176
Drug: Selenium (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (100 microg daily)
Trial: 9869176
Drug: Beta-carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (30 mg twice daily)
Trial: 2517495
Drug: Oxindanac 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxindanac 200 mg thrice daily
Trial: 2517495
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g thrice daily (positive control)
Trial: 194506
Drug: EG626 (cAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG626 (cAMP phosphodiesterase inhibitor)
Trial: 31515921
Drug: Oral IgG
RxNorm normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral IgG
Trial: 31515921
Drug: Non-oral IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-oral IgG
Trial: 27077121
Drug: VIS410 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS410 (2 mg/kg - 50 mg/kg)
Trial: 27077121
Drug: VIS410 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS410 (30 mg/kg)
Trial: 27077121
Drug: VIS410 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS410 (50 mg/kg)
Trial: 19254816
Drug: Yacon syrup
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yacon syrup (0.14 g fructooligosaccharides/kg/day)
Trial: 19254816
Drug: Yacon syrup
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yacon syrup (0.29 g fructooligosaccharides/kg/day)
Trial: 17197807
Drug: CD4 cell
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 cell count and plasma HIV‐1 RNA (pVL)‐guided treatment interruptions (GTI)
Trial: 17197807
Drug: Standard antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiretroviral therapy (control group)
Trial: 15976210
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of hyperbaric ropivacaine 0.5% (group Ropi‐7.5, n = 31)
Trial: 15976210
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐5, n = 30)
Trial: 15976210
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐7.5, n = 30)
Trial: 10528287
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) administered orally at 1 g twice daily
Trial: 10528287
Drug: Systemic cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic cyclosporin A (CSA) with dosage varying between 100 and 500 mg daily based on blood trough levels of 120-150 ng/ml
Trial: 8895005
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose interferon-alpha 2b 3 MU thrice weekly for 1 year
Trial: 8895005
Drug: Titrated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated dose interferon starting at 5 MU thrice weekly for 1 year
Trial: 6133481
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg and 50 mg
Trial: 31082669
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Radium-223 55 kBq/kg every six weeks × 5 doses plus docetaxel 60 mg/m2 q3w × 10 doses)
Trial: 31082669
Drug: Docetaxel alone
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel alone (75 mg/m2 every 3 weeks)
Trial: 22267599
Drug: Azithromycin (Azi)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (Azi) 250 mg/day
Trial: 20123314
Drug: Rate-adaptive pacing
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate-adaptive pacing (RAP) therapy
Trial: 15833782
Drug: Diphenhydramine-morphine mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine-morphine mixture (4.8:1 ratio)
Trial: 15833782
Drug: Diphenhydramine-morphine mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine-morphine mixture (1.2:1 ratio)
Trial: 31446213
Drug: Olaparib monotherapy
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib monotherapy (300 mg twice daily)
Trial: 29465210
Drug: Remaxol included
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remaxol included in infusion therapy before anesthesia
Trial: 26072359
Drug: Worth the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worth the Walk intervention (hour-long sessions twice weekly for four weeks)
Trial: 23208880
Drug: YF vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YF vaccine and Ig
Trial: 23208880
Drug: YF vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YF vaccine and saline placebo
Trial: 21802442
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine (0, 5, 10, 20 and 30 mg) during atomoxetine maintenance (80 mg/day)
Trial: 21802442
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine during atomoxetine maintenance (80 mg/day)
Trial: 19608354
Drug: Bupropion combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion combined with cognitive behavioral therapy and contingency management
Trial: 15139054
Drug: Docetaxel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (30 mg/m2 weekly for 6 weeks)
Trial: 3583091
Drug: DA agonists
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA agonists (DA, L-dopa, L-dopa plus carbidopa, nomifensine, amphetamine)
Trial: 25640832
Drug: Fast Track
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast Track intervention (10 years of treatment with various services)
Trial: 19660594
Drug: Moderate-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT)
Trial: 15769695
Drug: Heparin Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin Management Test (HMT)
Trial: 27760084
Drug: Gua sha
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Gua HC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gua sha therapy plus conventional treatment for 8 weeks
Trial: 27760084
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conventional treatment alone)
Trial: 25925031
Drug: Opioid-free anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free anesthesia with dexmedetomidine, lidocaine, and propofol infusions (Group DL)
Trial: 25925031
Drug: Opioid-based anesthesia
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-based anesthesia with remifentanil and propofol infusions (Group RF)
Trial: 23921331
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 6 lumbar facet joints with triamcinolone hexacetonide
Trial: 23921331
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of triamcinolone acetonide at 6 lumbar paravertebral points
Trial: 19384786
Drug: Avastin (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avastin (1.25 mg in 0.05 mL) every six weeks
Trial: 19384786
Drug: Lucentis (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucentis (0.05 mg in 0.05 mL) every four weeks
Trial: 11431744
Drug: 3 MU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU IFN-alpha2b 3 times a week plus ribavirin 1,000 mg/d for 12 months
Trial: 790129
Drug: Bencyclan (Fludilat)
RxNorm normalized name: bencyclane
DrugBank: Bencyclane (DB13488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencyclan (Fludilat) administered intravenously at a dosage of 500 mg per day
Trial: 30545448
Drug: Incremental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental treatment (pre‐procedural cefazolin plus vancomycin, intraprocedural bacitracin pocket wash, and 2‐day post‐procedural oral cephalexin)
Trial: 30545448
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (pre‐procedural cefazolin infusion)
Trial: 30545448
Drug: Incremental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental treatment
Trial: 24124893
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise intervention (12 weeks, twice weekly, cardiovascular and strength training, relaxation)
Trial: 15830221
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg alprazolam
Trial: 9700978
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alprazolam
Trial: 8467286
Drug: rhGM‐CSF alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF alone (concurrent control)
Trial: 3938925
Drug: Metrifonate treatment
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate treatment (MIT)
Trial: 21078465
Drug: SBIRT (Screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT (Screening, Brief Intervention, and Referral to Treatment) by emergency nurses
Trial: 16863482
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, without food (treatment A)
Trial: 16863482
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, with food (treatment B)
Trial: 16863482
Drug: Food alone
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food alone (treatment C, control)
Trial: 14644860
Drug: Oral pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pilocarpine (5 mg twice a day)
Trial: 11007680
Drug: 200 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/wk of intravenous iron dextran (IVID) for 5 weeks
Trial: 11007680
Drug: 500 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/wk of intravenous iron dextran (IVID) for 2 weeks
Trial: 1728443
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Trial: 1728443
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Trial: 2877386
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg a day)
Trial: 2877386
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg a day)
Trial: 29546560
Drug: Laparoscopic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic low anterior resection (L-LAR)
Trial: 27097042
Drug: Carbohydrate-Protein (CHO-P;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-Protein (CHO-P; 0.8 g carbohydrate·kg body mass [BM-1]·h-1 plus 0.4 g protein·kg BM-1·h-1)
Trial: 27097042
Drug: Isocaloric Carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric Carbohydrate (CHO; 1.2 g carbohydrate·kg BM-1·h-1)
Trial: 20636196
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) group